Profit Sheets

Lupin gets USFDA nod for generic product

March 24, 2022 02:35 PM

Lupin gets USFDA nod for generic product
Drug firm Lupin on Thursday said it has received approval from the US health regulator to market Sildenafil for Oral Suspension.

Drug firm Lupin on Thursday said it has received approval from the US health regulator to market Sildenafil for Oral Suspension, used to treat erectile dysfunction and pulmonary arterial hypertension, in the American market.

The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA), Sildenafil for Oral Suspension, 10 mg/mL, Lupin said in a statement.

Read More: Lupin receives USFDA approval for antibiotic Solosec

The Mumbai-based company’s product is the generic version of Viatris Specialty LLC’s Revatio. The product will be manufactured at Lupin’s Goa-based manufacturing facility, it added.

As per IQVIA MAT December 2021 data, Sildenafil for Oral Suspension, 10 mg/mL had estimated annual sales of USD 66 million in the US.

Source: PTI

Leave a comment

Your email address will not be published. Required fields are marked *

NSE Top Gainers/Losers
COMPANY LTP %CHNG VOLUME
ITC 253.75 1.83 1,26,68,576
M&M 807.10 1.73 48,32,584
JSWSTEEL 728.65 1.55 42,75,780
TATACONSUM 776.30 1.36 21,46,724
HINDUNILVR 2,043.00 1.34 16,38,568
COMPANY LTP %CHNG VOLUME
HINDALCO 569.90 -4.98 1,67,38,310
DIVISLAB 4,431.15 -2.37 3,48,495
APOLLOHOSP 4,525.45 -1.94 8,77,622
RELIANCE 2,634.00 -1.46 33,99,115
CIPLA 1,014.65 -1.39 12,17,592